Načítá se...

Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis

Objective: Aberrations in the PI3K/AKT/mTOR survival pathway in many cancers are the most common genomic abnormalities. The phytochemical and bioactive agent sulforaphane (SFN) has nutrigenomic potential in activating the expression of several cellular protective genes via the transcription factor n...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Mokhtari, Reza Bayat, Qorri, Bessi, Baluch, Narges, Sparaneo, Angelo, Fabrizio, Federico Pio, Muscarella, Lucia Anna, Tyker, Albina, Kumar, Sushil, Cheng, Hai-Ling Margaret, Szewczuk, Myron R., Das, Bikul, Yeger, Herman
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2021
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8310668/
https://ncbi.nlm.nih.gov/pubmed/34316328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.28011
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!